Illumina Awarded Genotyping Contract by SAIC-Frederick
News Feb 15, 2006
Illumina, Inc. has announced that it is has been awarded a genotyping services contract by SAIC-Frederick, Inc. under prime contract to the National Cancer Institute (NCI) to perform whole-genome SNP scans on over 2,500 prostrate case and control samples provided by the Institute.
The genotyping supports the Cancer Genetic Markers of Susceptibility (CGEMS), an NCI Strategic Initiative coordinated through the NCI's Division of Cancer Epidemiology and Genetics (DCEG), the NCI Core Genotyping Facility (CGF) and the NCI Office of Cancer Genomics (OCG).
The CGEMS initiative is designed to map susceptibility in prostrate and breast cancers, with the aim of understanding disease cause and progression, and then identifying strategies for prevention, earlier detection and treatment.
Illumina will use its Sentrix® HumanHap300 BeadChip and Infinium™ assay to perform the genotyping.
Illumina claims that, each HumanHap300 BeadChip can query over 317,000 SNP markers composed principally of "tagSNPs" identified and validated by the International HapMap Project.
Post-genotyping data analysis will be conducted under the guidance of NCI's Advanced Technology Center Core Genotyping Facility.
"We're very pleased to extend our relationship with the NCI," said Jay Flatley, Illumina President and CEO. "We're looking forward to engaging the capabilities of our world-class services organization to support the CGEMS initiative."
In treating inflammatory bowel disease (IBD), physicians can have a hard time telling which newly diagnosed patients have a high risk of severe inflammation or what therapies will be most effective. Now researchers report finding an epigenetic signature in patient cells that appears to predict inflammation risk in a serious type of IBD called Crohn’s disease.